High yield — cash cover is thin. A 5.7% indicated yield on a $0.43 quarterly dividend is covered on adjusted earnings — 53.4% of Pfizer's $3.22 adjusted diluted EPS in 2025. The cash tells a thinner story: dividends of about $9.8 billion took roughly 89% of free cash flow in the year to June 2026, and more than all of it in 2025. That is maintainable, not comfortable — and 2026 brought no raise.
Key risk: The patent / loss-of-exclusivity wave through 2028, on top of falling COVID revenue, squeezes the cash that funds the dividend — if free cash flow stays at or below the payout, maintaining it leans on the balance sheet.
Changes if: Free cash flow covers the dividend comfortably for a full year again, or it doesn't — another year with dividends above free cash flow, or a cut to fund the patent-cliff transition, changes this verdict.
- !Payout-coverage check: 53.4% of FY2025 adjusted diluted EPS ($1.72 ÷ $3.22) is covered, but cash is thinner: about $9.8B of dividends were ~89% of free cash flow in the year to June 28, 2026, and exceeded FY2025 free cash flow ($9.77B paid vs. $9.08B).
- ✓Yield check: 5.7% indicated ($0.43 × 4 ÷ $30.03, the Oct 23, 2026 close) is a real cash dividend from a real business, not return of capital — it passes on construction; the risk sits in coverage, not in how the yield is made.
- !Dividend growth check: Raises of ~2.4–2.5% a year in 2023–2025 ($1.64 → $1.68 → $1.72 a year, 16 years of annual increases through 2025), then a pause: $0.43 held for every quarter of 2026, Q4 included — growth stalled, not cut.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.